Evidence map›Paper›PMID 9399956›Full record

ArticleThe Journal of clinical investigation1997

Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid.

S M Monte, K Ghanbari, W H Frey, I Beheshti, P Averback, S L Hauser, H A Ghanbari, J R Wands

Open access · greenAbstract read
In one paragraph

Article in The Journal of clinical investigation, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 114 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Biomarkers for Alzheimer's Disease Early Diagnosis.Journal of personalized medicine · 2020
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

S M MonteMGH Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. delamont@helix.MGH.harvard.edu
K Ghanbari
W H Frey
I Beheshti
P Averback
S L Hauser
H A Ghanbari
J R Wands
Harvard University · US

Funding

PATHOGENESIS, IMMUNODIAGNOSIS AND THERAPY OF HCCR37CA035711 · NCI · RHODE ISLAND HOSPITAL (PROVIDENCE, RI) · PI WANDS, JACK R · 2000 to 2008
$2.9M
EFFECTS OF ALCOHOL ON THE LIVERR01AA002666 · NIAAA · RHODE ISLAND HOSPITAL (PROVIDENCE, RI) · PI WANDS, JACK R · 1985 to 2007
$2.6M
PATHOGENESIS, IMMUNODIAGNOSIS, AND THERAPY OF HCCR01CA035711 · NCI · RHODE ISLAND HOSPITAL (PROVIDENCE, RI) · PI WANDS, JACK R · 1985 to 1999
–
EFFECTS OF ALCOHOL ON THE LIVERR37AA002666 · NIAAA · MASSACHUSETTS GENERAL HOSPITAL · PI WANDS, JACK R · 1989 to 1997
–
NCI NIH HHS CA-35711NIAAA NIH HHS AA-02169NIAAA NIH HHS AA-02666
6 · The paper itself

Abstract

We have isolated a novel Alu sequence-containing cDNA, designated AD7c-NTP, that is expressed in neurons, and overexpressed in brains with Alzheimer's disease (AD). The 1,442-nucleotide AD7c-NTP cDNA encodes an approximately 41-kD protein. Expression of AD7c-NTP was confirmed by nucleic acid sequencing of reverse transcriptase PCR products isolated from brain. AD7c-NTP cDNA probes hybridized with 1. 4 kB mRNA transcripts by Northern blot analysis, and monoclonal antibodies generated with the recombinant protein were immunoreactive with approximately 41-45-kD and approximately 18-21-kD molecules by Western blot analysis. In situ hybridization and immunostaining studies localized AD7c-NTP gene expression in neurons. Using a quantitative enzyme-linked sandwich immunoassay (Ghanbari, K., I. Beheshti, and H. Ghanbari, manuscript submitted for publication) constructed with antibodies to the recombinant protein, AD7c-NTP levels were measured under code in 323 clinical and postmortem cerebrospinal fluid (CSF) samples from AD, age-matched control, Parkinson's disease, and neurological disease control patients. The molecular mass of the AD7c-NTP detected in CSF was approximately 41 kD. In postmortem CSF, the mean concentration of AD7c-NTP in cases of definite AD (9.2+/-8.2 ng/ml) was higher than in the aged control group (1.6+/-0.9; P < 0.0001). In CSF samples from individuals with early possible or probable AD, the mean concentration of AD7c-NTP (4.6+/-3.4) was also elevated relative to the levels in CSF from age-matched (1.2+/-0.7) and neurological disease (1.0+/-0.9) controls, and ambulatory patients with Parkinson's disease (1.8+/-1.1) (all P < 0.001). CSF levels of AD7c-NTP were correlated with Blessed dementia scale scores (r = 0. 66; P = 0.0001) rather than age (r = -0.06; P > 0.1). In vitro studies demonstrated that overexpression of AD7c-NTP in transfected neuronal cells promotes neuritic sprouting and cell death, the two principal neuroanatomical lesions correlated with dementia in AD. The results suggest that abnormal AD7c-NTP expression is associated with AD neurodegeneration, and during the early stages of disease, CSF levels correlate with the severity of dementia.

Indexed as

AgedAgingAlzheimer DiseaseAmino Acid SequenceAnimalsBase SequenceBrainDNA, ComplementaryGene ExpressionHumansMolecular Sequence DataNerve Tissue ProteinsRabbitsRNA, MessengerAD7c-NTPDNA, ComplementaryNerve Tissue ProteinsRNA, Messenger

Identifiers

PMID9399956
PMCPMC508522
OpenAlexW2031767797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.